We are developing a targeted therapy for Acute Myeloid Leukemia that are designed to address treatment resistance.

AML is the most commonly diagnosed adult leukemia with an estimated 23,000 newly diagnosed cases in the United States each year.  About 30% AML cases are driven by mutations in FLT3.  Most patients who receive either Quizartinib (front line therapy) or Gilteritinib (Relapsed Refractory) as treatment, eventually have disease progression either due to the emergence of other FLT3 mutations or escape mechanisms.  The multitude of FLT3 clones requires constant pan-FLT3 inhibition to avoid resistant mutations while simultaneously inhibiting escape mechanisms.

We develop the best-in-class highly efficacious and selective pan-variant FLT3 and IRAK4 inhibitor that addresses the limitations of current therapies by targeting clinically relevant FLT3 mutations and escape mechanisms at the same time.